Biogen Inc. (BIIB)
NASDAQ
Real-time Data
01:30 PM
Day's Range
213.9952 wk Range
131.52Overview - BIIB - Biogen Inc.
Key Statistics
Valuation
Enterprise Value
39.10B
P/E (Trailing)
‪38.43‬
P/E (Forward)
‪13.10‬
PEG Ratio
‪-0.45‬
Price / Sales (TTM)
‪3.19‬
Price / Book
‪1.69‬
EV / EBITDA
‪11.64‬
Profitability
Gross Margin
‪71.60%‬
Profit Margin
‪8.32%‬
Operating Margin
‪25.05%‬
Return on Assets
‪5.20%‬
Return on Equity
‪4.57%‬
Ownership
Shares Outstanding
147.70M
Float
147.21M
Short % of Shares Outstanding
‪4.11%‬
Held by Insiders
‪0.18%‬
Held by Institutions
‪99.51%‬
Price stats
Beta
‪0.16‬
50-Day Avg
‪205.27‬
200-Day Avg
‪187.99‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
36 analysts
Average price target
‪$ 237.59‬Shariah Compliance
Report Date: Feb 19, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - BIIB - Biogen Inc.
Peers - BIIB - Biogen Inc.
Peer Comparison
Compared with companies in Drug Manufacturers - General listed on NASDAQ.
Profile Summary - BIIB - Biogen Inc.
About
Biogen Inc. is a biotechnology company that discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company offers products such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
